BERLIN (Reuters) -German pharma company Bayer reported positive study results for its anticoagulant asundexian on Sunday, two years after a research setback for the promising blood thinner candidate.
In a Phase III study, a daily dose of 50 milligrams significantly reduced the risk of ischemic stroke compared with a placebo, Bayer said.
Detailed results from the OCEANIC-STROKE study will be presented at an upcoming scientific congress, said Bayer.
Bayer added that it plans to speak with health authorities worldwide in preparation for the submission of marketing authorisation applications.
Bayer had originally predicted that asundexian would have peak sales potential of more than 5 billion euros ($5.76 billion) - more than any of its other drugs.
At the end of 2023, the company had a major setback with the drug after it failed in a pivotal clinical trial involving patients with atrial fibrillation and a risk of stroke.
($1 = 0.8687 euros)
(Reporting by Joern Poltz. Writing by Miranda Murray. Editing by Jane Merriman)
LATEST POSTS
- 1
The most effective method to Pick the Right Volvo XC40 Trim for Your Way of life - 2One perk to marrying Richard Marx later in life? 'We don't have time' for stupid arguments, says Daisy Fuentes.
- 3Coffee Prices Finish Higher on Brazil Cop Concerns
- 4First Houthi launch toward Israel since war began triggers alerts across the Negev
- 5Banks for High Fixed Store Rates: Augment Your Investment funds
- Tech for Wellbeing: Applications and Devices for a Better You
- Explosions at Burundi ammunition depot kill civilians, witnesses say
- Everyday Seasonal Positions That Compensate Fairly in the US
- EU agrees on agriculture safeguards as fronts harden in Mercosur deal
- Are Iraqi militias crossing into Iran to support Iran's war effort?
- Famous Kitchen Finishing Styles For 2024
- Tesla plans to expand production at German car plant
- Cuba says 33 have died of mosquito-borne illnesses as epidemic rages
- The most effective method to Really Adjust Hypothesis and Practice in Your Brain science Studies
